Beijing Bohui Innovation Biotechnology (SHE:300318) received regulatory approval from China's medical products administrator for a third class in vitro diagnostic reagent.
The nucleic acid detection kit targets rotavirus, norovirus, enteric adenovirus, astrovirus and sapovirus in stool samples, according to a May 31 filing with the Shenzhen bourse.
The certificate is valid until May 28, 2030.